- Home
- NCRA vs CHRO Comparison
NCRA vs CHRO Comparison
Compare NCRA & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCRA
- CHRO
- Stock Information
- Founded
- NCRA 2002
- CHRO 2002
- Country
- NCRA Taiwan
- CHRO United States
- Employees
- NCRA N/A
- CHRO N/A
- Industry
- NCRA Farming/Seeds/Milling
- CHRO
- Sector
- NCRA Consumer Staples
- CHRO
- Exchange
- NCRA Nasdaq
- CHRO Nasdaq
- Market Cap
- NCRA 11.7M
- CHRO 11.3M
- IPO Year
- NCRA N/A
- CHRO 2024
- Fundamental
- Price
- NCRA $0.88
- CHRO $1.68
- Analyst Decision
- NCRA
- CHRO Strong Buy
- Analyst Count
- NCRA 0
- CHRO 1
- Target Price
- NCRA N/A
- CHRO N/A
- AVG Volume (30 Days)
- NCRA 17.1K
- CHRO 104.9K
- Earning Date
- NCRA 01-01-0001
- CHRO 03-04-2025
- Dividend Yield
- NCRA N/A
- CHRO N/A
- EPS Growth
- NCRA N/A
- CHRO N/A
- EPS
- NCRA N/A
- CHRO N/A
- Revenue
- NCRA $20,483,694.00
- CHRO N/A
- Revenue This Year
- NCRA N/A
- CHRO N/A
- Revenue Next Year
- NCRA N/A
- CHRO N/A
- P/E Ratio
- NCRA N/A
- CHRO N/A
- Revenue Growth
- NCRA N/A
- CHRO N/A
- 52 Week Low
- NCRA $0.70
- CHRO $0.45
- 52 Week High
- NCRA $2.09
- CHRO $4.84
- Technical
- Relative Strength Index (RSI)
- NCRA 46.85
- CHRO 50.49
- Support Level
- NCRA $0.80
- CHRO $1.59
- Resistance Level
- NCRA $0.89
- CHRO $1.99
- Average True Range (ATR)
- NCRA 0.06
- CHRO 0.29
- MACD
- NCRA -0.00
- CHRO -0.06
- Stochastic Oscillator
- NCRA 46.84
- CHRO 41.44
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with expert consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.